Drug Trial Radar · NCT01132040
Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions
Last checked: Nov 19, 2026Latest source record: May 27, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 2006
Primary completion
Sep 2006
Study completion Sep 2006
Sponsor
- Lead sponsor
- Dr. Reddy's Laboratories Limited, IndiaIndustry
- Sponsor type
- Industry
- First posted
- May 27, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the bioavailability of Primidone 50 mg tablets of Dr.Reddy's comparing with that of Mysoline@ tablets of Yamanouchi Pharma Technologies Inc, in healthy, adult, human subjects under fasting conditions.
Conditions
- Healthy
Interventions
PrimidoneDrug
Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bioequivalence based on Cmax and AUC parametersTime frame: 2 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bioserve Clinical Research Pvt. Ltd,
HYD, Andhra Pradesh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.